TPST logo

TEMPEST THERAPEUTICS INC

TPSTNASDAQ
🏆 #4907 by market capEarnings Nov 3 · PostUS Equity
$0.82▼ $0.03 (−3.82%)
After hours · at close
🔔
Track TPST
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 3.8%
7d▼ 14.3%
14d▲ 6.1%
30d▼ 24.4%
ytd▼ 71.6%
1y▼ 92.0%
🏦Market Cap
$13M
Small Cap
📈Revenue Growth (YoY)
-6.3%
Declining
📊Gross Margin
-46.7%
Thin
💵FCF Margin
—
⚖️P/S Ratio
44.7x
Expensive
Otter Score
68
Fair

Trading Snapshot

Day Range
$0.81 – $0.82
52-Week Range
$0.74 – $12.23
Volume
$2.81B
Avg Volume
$3.53B
Shares Outstanding
16.0M
Next Earnings
Nov 26, 2026

Fundamentals Snapshot

Annual Revenue
$297,336
Last Q Revenue
$80,326
P/E Ratio
—
P/S Ratio
44.7x
EPS (TTM)
$-4.49
Dividend Yield
—
Dilution (1yr)
−85.1%

Why Investors Own TPST

  • ✓High-growth profile — revenue up +4.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 43% gross margin and 15% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TPST logo

TEMPEST THERAPEUTICS INC

TPST
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$27M▼ −36.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$27M▼ −19.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
4.1M▼ −85.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$434K▼ −$15M YoY
StockOtter · stockotter.space

About TEMPEST THERAPEUTICS INC

Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$1.08
▲ +32.9% Upside
High Target$1.20
Low Target$0.88
Based on 25 analysts

Latest News & Updates

🚀
Reuters·2h ago

TEMPEST THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift TPST price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

TEMPEST THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.